LifeMD, Inc. - LFMD STOCK NEWS

LifeMD, Inc. (NASDAQ: LFMD) has issued a response to a damaging report from anonymous short-seller Culper Research, citing numerous inaccuracies. The company emphasizes its commitment to transparency and patient care, outlining its quality controls and physician vetting processes. CEO Justin Schreiber criticized the credibility of Culper’s claims, specifically regarding LifeMD's licensing practices and operational integrity. LifeMD aims for a complete transition to its digital health platform, Veritas MD, by Q2 2021. The company affirms its robust telehealth infrastructure and dedication to shareholder trust.

LifeMD (NASDAQ: LFMD) recently addressed false claims posted about the company and its executives by a purported research firm. The company maintains it has had no contact with this firm and is taking legal action with its counsel, Quinn Emanuel Urquhart & Sullivan, LLP, to investigate the source of the claims. LifeMD has stated its commitment to transparency and compliance, urging anyone with information to contact them. The company stands by its regulatory disclosures and reassures stakeholders of its operational integrity.

LifeMD, Inc. (NASDAQ: LFMD) has launched NavaMD, a tele-dermatology brand, expanding its portfolio into the growing $40 billion telehealth market. The service offers personalized dermatology care across all 50 states, focusing on conditions like acne and rosacea. This brand is the third successful launch in four years, aimed at acquiring female patients through targeted marketing. NavaMD combines telemedicine with proprietary skincare products licensed from Restorsea, enhancing its treatment offerings. The approach promotes recurring revenues and shareholder value through a user-friendly, three-step customer journey.

LifeMD, Inc. (NASDAQ: LFMD) reported impressive financial results for 2020, with revenue soaring 199% to $37.3 million. In Q4 2020, revenue reached $12.9 million, a 227% increase year-over-year, largely driven by a 293% rise in telemedicine product sales. The company’s annual recurring revenue (ARR) surged 443% to $53.4 million by year-end. Despite significant growth, the company recorded a net loss of $63.4 million for 2020, impacted by high operating costs. For 2021, LifeMD forecasts revenues between $85 million to $95 million.

LifeMD (NASDAQ: LFMD), a telehealth leader, is set to discuss its fourth-quarter and full-year financial results for 2020 on March 29, 2021, at 4:30 p.m. ET. An earnings press release will precede the call. Participants can join via toll-free and international numbers with a conference ID of 4067431. The call will also be available via webcast and can be replayed until April 12, 2021. LifeMD provides direct-to-patient telehealth services, enhancing healthcare accessibility with licensed providers and convenient home delivery.

LifeMD, Inc. (NASDAQ: LFMD) announced on March 16, 2021, that its Compensation Committee granted an equity award to a new employee on March 15, 2021. The award consists of options to purchase 90,000 shares of common stock at an exercise price of $19.61, equal to the stock's closing price on the grant date. The options will vest monthly over three years, contingent on the employee's continued service, and have a five-year term. This award aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.

LifeMD, Inc. (NASDAQ: LFMD) has been invited to the 33rd Annual ROTH Growth Conference, taking place virtually from March 15-17, 2021. CEO Justin Schreiber, CFO Marc Benathen, and Chief Business Officer Corey Deutsch will engage with investors and analysts. A key topic will be the launch of the company’s new subscription-based primary care and concierge telehealth services, aimed at expanding its patient base. LifeMD anticipates Q1 2021 revenues to exceed $17 million, reflecting a 295% increase year-over-year, with subscriptions projected to contribute over 80% of this revenue.

LifeMD (NASDAQ: LFMD) expects first quarter 2021 revenue to exceed $17 million, a rise of over 295% year-over-year. CEO Justin Schreiber highlighted an annualized run-rate exceeding $68 million, with subscriptions now constituting over 80% of revenue, driven by Shapiro MD™ products. The upcoming launch of concierge telehealth services aims to enhance patient accessibility and attract new users. CFO Marc Benathen noted that a recent $14 million private placement supports aggressive growth initiatives including expanding their digital health ecosystem.

Conversion Labs has rebranded itself as LifeMD, Inc., trading under the new ticker symbol LFMD on Nasdaq. This change reflects the company's transformation from a healthcare marketing business to a provider of direct-to-patient telehealth services. LifeMD aims to revolutionize healthcare accessibility with its new subscription-based primary care service. In its preliminary 2020 results, the company reported a 205% revenue increase to $38 million, and anticipates an annual recurring revenue of $26 million, up 525% year-over-year.